Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Stopped early · Phase 2

Conditions studied: Multiple Myeloma

In brief

The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab, in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma.

Key facts

Study ID
NCT04892446
Run by
Gilead Sciences
People needed
36
Starts
2021-11-09
Expected to finish
2024-04-25
Last updated by the study team
2025-05-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.